C9089 HCPCS code: Bupivacaine, collagen-matrix implant, 1 mg
C9089 is the HCPCS Level II code for bupivacaine, collagen-matrix implant, 1 mg. CMS terminated C9089 on 2025-12-31; do not bill it for later dates of service. In 2024 Medicare paid an average of $0.66 per service for C9089 across 28,653 services. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met. Medicare volume fell 22% from 2022 to 2024 (36,540 to 28,653 services). In 2024, about 9 clinicians billed Medicare for C9089 for 111 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | O1E — Other drugs |
| Added | 2022-01-01 |
| Last action effective | 2026-01-01 |
| Terminated | 2025-12-31 |
Who bills C9089 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 9 |
| Medicare beneficiaries | 111 |
| States with claims | 3 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for C9089, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 36,540 | 140 | $0.76 | $0.61 |
| 2023 | 49,643 | 187 | $0.83 | $0.66 |
| 2024 | 28,653 | 111 | $0.83 | $0.66 |
States with the most C9089 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 13,333 | $0.66 |
| California | 12,000 | $0.67 |
| Delaware | 407 | $0.67 |
What changed for C9089
- 2022-01-01: C9089 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9089?
C9089 is the HCPCS Level II code for bupivacaine, collagen-matrix implant, 1 mg. Short descriptor: "Bupivacaine implant, 1 mg".
How much does Medicare pay for C9089?
In 2024, the average Medicare payment was $0.66 per service (average allowed $0.83).
Does Medicare cover C9089?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Related C90 codes
- C9014 — Injection, cerliponase alfa, 1 mg
- C9015 — Injection, c-1 esterase inhibitor (human), haegarda, 10 units
- C9016 — Injection, triptorelin extended release, 3.75 mg
- C9021 — Injection, obinutuzumab, 10 mg
- C9022 — Injection, elosulfase alfa, 1mg
- C9023 — Injection, testosterone undecanoate, 1 mg
- C9024 — Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
- C9025 — Injection, ramucirumab, 5 mg
- C9026 — Injection, vedolizumab, 1 mg
- C9027 — Injection, pembrolizumab, 1 mg
- C9028 — Injection, inotuzumab ozogamicin, 0.1 mg
- C9029 — Injection, guselkumab, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9089
- Watch C9089 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9089
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.